share_log

Novavax | 8-K: Asset Purchase Agreement

Novavax | 8-K: Asset Purchase Agreement

诺瓦瓦克斯医药 | 8-K：资产购买协议
美股SEC公告 ·  2024/12/31 06:30

Moomoo AI 已提取核心信息

On December 30, 2024, Novavax CZ a.s., a subsidiary of Novavax Inc., finalized the sale of its biologics manufacturing campus in Bohumil, Jevany, Czech Republic to Novo Nordisk Production Czech s.r.o. for $200 million. The transaction, announced on December 3, 2024, included the transfer of properties, moveable assets, equipment, related contracts, and certain employees.The purchaser paid $180 million at closing, following a $10 million initial payment in September 2024. An additional $10 million was placed in escrow, to be released after 12 months, subject to potential claims. Novavax also received approximately $2.6 million as reimbursement for operational costs incurred between the announcement and completion of the sale.This strategic move aligns with Novavax's asset optimization efforts. The company expects to provide further details in its upcoming Annual Report on Form 10-K for the year ending December 31, 2024.
On December 30, 2024, Novavax CZ a.s., a subsidiary of Novavax Inc., finalized the sale of its biologics manufacturing campus in Bohumil, Jevany, Czech Republic to Novo Nordisk Production Czech s.r.o. for $200 million. The transaction, announced on December 3, 2024, included the transfer of properties, moveable assets, equipment, related contracts, and certain employees.The purchaser paid $180 million at closing, following a $10 million initial payment in September 2024. An additional $10 million was placed in escrow, to be released after 12 months, subject to potential claims. Novavax also received approximately $2.6 million as reimbursement for operational costs incurred between the announcement and completion of the sale.This strategic move aligns with Novavax's asset optimization efforts. The company expects to provide further details in its upcoming Annual Report on Form 10-K for the year ending December 31, 2024.
2024年12月30日，Novavax CZ a.s.（Novavax Inc.的子公司）完成了位于捷克共和国杰瓦尼博胡米尔的生物制品制造校园的销售，售予Novo Nordisk Production Czech s.r.o.，交易金额为20000万美金。该交易于2024年12月3日公布，包括不动产、可动资产、设备、相关合同及部分员工的转让。买方在交易时支付了18000万美金，之前2024年9月已支付1000万美金的初始款项。另有1000万美金被放入托管账户，将在12个月后释放，但需视潜在索赔而定。Novavax还获得约260万美金的运营成本补偿，作为交易公告与完成之间发生的费用。这一战略性举措与Novavax的资产优化努力相一致。公司预计将在其2024年12月31日财年的即将发布的10-k年度报告中提供更多细节。
2024年12月30日，Novavax CZ a.s.（Novavax Inc.的子公司）完成了位于捷克共和国杰瓦尼博胡米尔的生物制品制造校园的销售，售予Novo Nordisk Production Czech s.r.o.，交易金额为20000万美金。该交易于2024年12月3日公布，包括不动产、可动资产、设备、相关合同及部分员工的转让。买方在交易时支付了18000万美金，之前2024年9月已支付1000万美金的初始款项。另有1000万美金被放入托管账户，将在12个月后释放，但需视潜在索赔而定。Novavax还获得约260万美金的运营成本补偿，作为交易公告与完成之间发生的费用。这一战略性举措与Novavax的资产优化努力相一致。公司预计将在其2024年12月31日财年的即将发布的10-k年度报告中提供更多细节。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Scorpius Holdings
    SCPX
    -- 0.551
    SciSparc
    SPRC
    -- 0.5279
    Hepion Pharmaceuticals
    HEPA
    -- 0.6370
    Cue Biopharma
    CUE
    -- 1.390
    Viracta Therapeutics
    VIRX
    -- 0.223

    解锁榜首股票